|
Gene: CUL4A |
Gene summary for CUL4A |
Gene summary. |
Gene information | Species | Human | Gene symbol | CUL4A | Gene ID | 8451 |
Gene name | cullin 4A | |
Gene Alias | CUL4A | |
Cytomap | 13q34 | |
Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | Q13619 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8451 | CUL4A | CCI_1 | Human | Cervix | CC | 1.81e-08 | 7.52e-01 | 0.528 |
8451 | CUL4A | CCI_2 | Human | Cervix | CC | 9.41e-13 | 1.14e+00 | 0.5249 |
8451 | CUL4A | CCI_3 | Human | Cervix | CC | 1.52e-07 | 6.15e-01 | 0.516 |
8451 | CUL4A | sample3 | Human | Cervix | CC | 2.29e-02 | 1.25e-01 | 0.1387 |
8451 | CUL4A | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.59e-05 | -3.04e-01 | 0.0155 |
8451 | CUL4A | HTA11_866_3004761011 | Human | Colorectum | AD | 2.18e-02 | -2.46e-01 | 0.096 |
8451 | CUL4A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.41e-11 | 7.83e-01 | 0.281 |
8451 | CUL4A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.44e-04 | 6.25e-01 | 0.3859 |
8451 | CUL4A | A001-C-207 | Human | Colorectum | FAP | 2.58e-02 | -1.95e-01 | 0.1278 |
8451 | CUL4A | A015-C-203 | Human | Colorectum | FAP | 8.69e-25 | -3.23e-01 | -0.1294 |
8451 | CUL4A | A015-C-204 | Human | Colorectum | FAP | 3.92e-05 | -2.41e-01 | -0.0228 |
8451 | CUL4A | A014-C-040 | Human | Colorectum | FAP | 6.73e-03 | -3.34e-01 | -0.1184 |
8451 | CUL4A | A002-C-201 | Human | Colorectum | FAP | 5.55e-11 | -2.84e-01 | 0.0324 |
8451 | CUL4A | A002-C-203 | Human | Colorectum | FAP | 1.12e-03 | -1.75e-01 | 0.2786 |
8451 | CUL4A | A001-C-119 | Human | Colorectum | FAP | 5.14e-03 | -2.24e-01 | -0.1557 |
8451 | CUL4A | A001-C-108 | Human | Colorectum | FAP | 2.13e-12 | -1.80e-01 | -0.0272 |
8451 | CUL4A | A002-C-205 | Human | Colorectum | FAP | 4.60e-18 | -3.02e-01 | -0.1236 |
8451 | CUL4A | A001-C-104 | Human | Colorectum | FAP | 5.32e-04 | -1.80e-01 | 0.0184 |
8451 | CUL4A | A015-C-005 | Human | Colorectum | FAP | 1.25e-02 | -1.45e-01 | -0.0336 |
8451 | CUL4A | A015-C-006 | Human | Colorectum | FAP | 6.71e-13 | -9.44e-02 | -0.0994 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719310 | Cervix | CC | intrinsic apoptotic signaling pathway | 85/2311 | 288/18723 | 4.56e-15 | 6.46e-12 | 85 |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:19021056 | Cervix | CC | regulation of leukocyte differentiation | 61/2311 | 279/18723 | 5.16e-06 | 1.29e-04 | 61 |
GO:20000453 | Cervix | CC | regulation of G1/S transition of mitotic cell cycle | 37/2311 | 142/18723 | 6.33e-06 | 1.53e-04 | 37 |
GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
GO:19021064 | Cervix | CC | negative regulation of leukocyte differentiation | 29/2311 | 102/18723 | 1.02e-05 | 2.29e-04 | 29 |
GO:00000824 | Cervix | CC | G1/S transition of mitotic cell cycle | 49/2311 | 214/18723 | 1.16e-05 | 2.48e-04 | 49 |
GO:19028062 | Cervix | CC | regulation of cell cycle G1/S phase transition | 41/2311 | 168/18723 | 1.18e-05 | 2.51e-04 | 41 |
GO:00073466 | Cervix | CC | regulation of mitotic cell cycle | 88/2311 | 457/18723 | 1.26e-05 | 2.60e-04 | 88 |
GO:19019903 | Cervix | CC | regulation of mitotic cell cycle phase transition | 63/2311 | 299/18723 | 1.27e-05 | 2.60e-04 | 63 |
GO:004563710 | Cervix | CC | regulation of myeloid cell differentiation | 48/2311 | 210/18723 | 1.49e-05 | 2.93e-04 | 48 |
GO:00448434 | Cervix | CC | cell cycle G1/S phase transition | 53/2311 | 241/18723 | 1.76e-05 | 3.32e-04 | 53 |
GO:00459316 | Cervix | CC | positive regulation of mitotic cell cycle | 32/2311 | 121/18723 | 1.88e-05 | 3.47e-04 | 32 |
GO:002261310 | Cervix | CC | ribonucleoprotein complex biogenesis | 88/2311 | 463/18723 | 2.11e-05 | 3.82e-04 | 88 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0517016 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0517017 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa051704 | Colorectum | MSS | Human immunodeficiency virus 1 infection | 69/1875 | 212/8465 | 2.66e-04 | 1.98e-03 | 1.21e-03 | 69 |
hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa051705 | Colorectum | MSS | Human immunodeficiency virus 1 infection | 69/1875 | 212/8465 | 2.66e-04 | 1.98e-03 | 1.21e-03 | 69 |
hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa051706 | Colorectum | FAP | Human immunodeficiency virus 1 infection | 51/1404 | 212/8465 | 2.98e-03 | 1.29e-02 | 7.87e-03 | 51 |
hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa051707 | Colorectum | FAP | Human immunodeficiency virus 1 infection | 51/1404 | 212/8465 | 2.98e-03 | 1.29e-02 | 7.87e-03 | 51 |
hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa034205 | Esophagus | HGIN | Nucleotide excision repair | 29/1383 | 63/8465 | 2.96e-08 | 5.36e-07 | 4.26e-07 | 29 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CUL4A | SNV | Missense_Mutation | novel | c.359N>A | p.Pro120Gln | p.P120Q | Q13619 | protein_coding | tolerated(0.83) | benign(0.001) | TCGA-78-7536-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
CUL4A | SNV | Missense_Mutation | novel | c.958N>T | p.Ala320Ser | p.A320S | Q13619 | protein_coding | tolerated(1) | benign(0.003) | TCGA-86-6851-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CUL4A | SNV | Missense_Mutation | novel | c.1172A>G | p.Lys391Arg | p.K391R | Q13619 | protein_coding | tolerated(0.1) | benign(0.052) | TCGA-97-7546-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Targeted Molecular therapy | tarceva | SD |
CUL4A | SNV | Missense_Mutation | novel | c.1934N>A | p.Gly645Glu | p.G645E | Q13619 | protein_coding | deleterious(0) | possibly_damaging(0.629) | TCGA-21-1080-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CUL4A | SNV | Missense_Mutation | novel | c.971N>G | p.Gln324Arg | p.Q324R | Q13619 | protein_coding | tolerated(0.29) | benign(0.01) | TCGA-56-8305-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CUL4A | SNV | Missense_Mutation | novel | c.680N>G | p.Tyr227Cys | p.Y227C | Q13619 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-F7-A50I-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CUL4A | insertion | In_Frame_Ins | novel | c.1309_1310insTGATCC | p.Ile438_Leu439dup | p.I438_L439dup | Q13619 | protein_coding | TCGA-CR-7394-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
CUL4A | SNV | Missense_Mutation | novel | c.634N>C | p.Ser212Arg | p.S212R | Q13619 | protein_coding | tolerated(0.06) | benign(0.312) | TCGA-V1-A8WL-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
CUL4A | SNV | Missense_Mutation | c.1400N>T | p.Ala467Val | p.A467V | Q13619 | protein_coding | deleterious(0) | possibly_damaging(0.681) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CUL4A | SNV | Missense_Mutation | novel | c.1244N>T | p.Ser415Leu | p.S415L | Q13619 | protein_coding | tolerated(0.1) | benign(0.288) | TCGA-D7-A6F0-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8451 | CUL4A | ENZYME, DNA REPAIR, CLINICALLY ACTIONABLE | inhibitor | CHEMBL848 | LENALIDOMIDE | |
8451 | CUL4A | ENZYME, DNA REPAIR, CLINICALLY ACTIONABLE | inhibitor | CHEMBL468 | THALIDOMIDE | |
8451 | CUL4A | ENZYME, DNA REPAIR, CLINICALLY ACTIONABLE | inhibitor | CHEMBL43452 | POMALIDOMIDE |
Page: 1 |